The National Cancer Institute (NCI) seeks capable licensees interested in commercializing T cell receptor (TCR)-engineered T cells expressing murine/human hybrid receptors.
The National Cancer Institute (NCI) seeks licensees for matched patient-derived 3D Isocitrate Dehydrogenase (IDH)-mutant glioma cell lines, 403L and 403H, generated from the same patient before and after malignant transformation from WHO grade 2 to WHO grade 4 disease. This research material provides an opportunity to study IDH-mutant glioma progression, temozolomide-associated hypermutation, invasion, metabolism, and treatment resistance.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for a collection of T cell receptors (TCRs) that specifically target HPV 6 or HPV 11 antigens.
This technology includes a novel apparatus and method that utilizes Electrochemical Impedance Spectroscopy (EIS) to assess the integrity of epithelial cell membranes non-destructively. By applying frequency-modulated voltage signals and facilitating fluid exchange on both sides of the epithelial tissue, this technology allows researchers to characterize membrane-specific responses with unprecedented accuracy.
NCI seeks research co-development and/or potential licensees for a potential novel treatment for triple-negative breast cancer (TNBC) with acetalax (oxyphenisatin acetate).
The National Cancer Institute (NCI) seeks licensees for human T-cell lines, C8166 and C8166-45, transformed by HTLV-1. C8166-45, a subclone of C8166, contains three transcriptionally active proviruses useful for testing biological activities involved in T-cell immortalization and growth.
The National Cancer Institute is seeking research co-development partners and licensing collaborators to accelerate the development and commercialization of innovative bifunctional antibody fusion molecules designed to activate and expand engineered TCR-expressing cells, advancing next-generation cancer immunotherapies.